According to FutureWise analysis the market for ankylosing spondylitis in 2023 was US$ 5.82 billion, and is expected to reach US$ 11.2 billion by 2031 at a CAGR of 8.52%.
Ankylosing spondylitis is a type of arthritis characterized by inflammation of the joints and ligaments in the spine, as well as peripheral joints such as those in the hips, knees, and ankles. This inflammation can lead to joint stiffness, significantly affecting movement and flexibility. In more severe cases, it may result in the fusion of vertebrae, which further decreases spinal flexibility and increases rigidity.
In addition to spinal symptoms, individuals with ankylosing spondylitis may experience a range of other complications as the condition can also impact different body systems. Common associated conditions include uveitis (an eye disease), psoriasis (a skin condition), and inflammatory bowel disease.
The main symptoms of ankylosing spondylitis include pain and stiffness in the lower back and hips. Over time, this pain may radiate to other parts of the spine and body, often intensifying during periods of rest or inactivity. Patients may find that sitting for extended periods or lying down at night can exacerbate discomfort, while movement and exercise generally help alleviate pain.
While there is currently no definitive cure for ankylosing spondylitis, several treatment options exist to manage its symptoms effectively. These treatments often include physical and occupational therapies aimed at improving mobility and posture. Additionally, various medications can be prescribed to relieve pain, reduce inflammation, enhance posture and body mechanics, and potentially slow the progression of the disease. With appropriate management, many individuals with ankylosing spondylitis are able to maintain productive and fulfilling lives.
FutureWise Market Research has published a report that provides an insightful analysis of Ankylosing Spondylitis Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=8996&type=requestsample
Ankylosing Spondylitis Market Segmentation:
By Drug
- Cosentyx
- Humira
- Simponi
- Remicade
- Embrel
- Cimzia
By Molecule Type
- Small Molecules
- Biologics
- Biosimilars
By Route of Administration
- Oral
- Parenteral
By End User
- Hospitals
- Clinics
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Ankylosing Spondylitis Market:
- AbbVie Inc.
- Janssen Pharmaceuticals Inc.
- Pfizer Inc.
- Sandoz International GmbH.
- Amgen Inc.
- Protalix BioTherapeutics, Inc.
- Reliance Life Sciences Pvt. Ltd.
- Momenta Pharmaceuticals Inc.
- Celgene Corporation
- Regeneron Pharmaceuticals
- MerckCo. Inc.
- Johnson and Johnson Services, Inc.
- UCB Inc.
- Novartis AG
- Samsung Bioepis Co., Ltd.
- Biothera Pharmaceuticals, Inc.
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=8996&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Ankylosing Spondylitis Market By Drug, By Molecule Type, By Route of Administration, By End User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
